SCYXMEDIUM SIGNALFINANCIAL10-K

SCYX showed meaningful improvement in operating cash flow and profitability metrics while completing a significant deleveraging that reduced total liabilities by 73%.

The company appears to have undergone substantial financial restructuring, converting from a heavily leveraged position to a much cleaner balance sheet while simultaneously improving operational cash burn. However, the shift in risk factor language from ibrexafungerp to SCY-247 suggests a strategic pivot that investors should monitor, particularly given the company's limited commercial track record and single approved product licensed to GSK.

Comparing 2026-03-04 vs 2025-03-12View on EDGAR →
FINANCIAL ANALYSIS

SCYX demonstrated notable financial improvement with operating cash flow burn substantially reduced and net losses meaningfully narrowed year-over-year. The company completed a major balance sheet restructuring, cutting total liabilities by 73% while maintaining adequate liquidity with cash increasing to $21.3M. Despite some asset reduction, the overall financial picture signals improved operational efficiency and a much stronger capital structure, though R&D spending declined modestly as the company appears to be shifting focus between drug candidates.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+78%
-$24.0M→-$5.3M

Operating cash flow surged 78% — exceptional cash generation, highest quality earnings signal.

Current Liabilities
Balance Sheet
-76.2%
$24.1M→$5.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-72.9%
$35.6M→$9.7M

Liabilities reduced 72.9% — deleveraging improves balance sheet strength and financial flexibility.

Net Income
P&L
+59.6%
-$21.3M→-$8.6M

Net income grew 59.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+56.7%
-$37.1M→-$16.1M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-44.1%
$72.2M→$40.4M

Current assets declined 44.1% — monitor working capital adequacy and short-term liquidity.

Interest Expense
P&L
-39.8%
$5.2M→$3.1M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Total Assets
Balance Sheet
-34.9%
$90.6M→$59.0M

Total assets contracted 34.9% — asset sales, write-downs, or balance sheet optimization underway.

Cash & Equivalents
Balance Sheet
+32.4%
$16.1M→$21.3M

Cash position surged 32.4% — strong cash generation or capital raise providing significant financial cushion.

R&D Expense
P&L
-15.6%
$26.4M→$22.3M

R&D spending cut 15.6% — could signal cost discipline or concerning reduction in innovation investment.

LANGUAGE CHANGES
NEW — 2026-03-04
PRIOR — 2025-03-12
ADDED
Excludes 890,899 shares of the registrant's Common Stock held by executive officers and directors outstanding at June 30, 2025.
As of March 1, 2026, there were 44,663,832 shares of the registrant s Common Stock outstanding .
The following is a summary of the principal risk factors: We have a limited history of profitability, we have only one product approved for commercial sale that is licensed to GlaxoSmithKline Intellectual Property (No.3) Limited (GSK), and to date we have generated limited revenue from product sales.
Although the oral formulation of SCY-247 has been granted Qualified Infectious Disease Product status and Fast Track designation, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that SCY-247 will ultimately be approved by the FDA.
We have only submitted one NDA and one supplemental NDA before, and we may be unable to do so for SCY-247 or any future product candidate we may seek to develop.
We expect that SCY-247 and any future product candidates we may seek to develop will face competition, and most of our competitors have significantly greater resources than we do.
SCY-247 or any other future product candidates we may seek to develop, may still face future development and regulatory difficulties.
If we experience problems with any of these third parties, the manufacturing of SCY-247 could be delayed.
is dedicated to advancing innovative solutions for severe rare diseases, with our lead program in the treatment and prevention of difficult-to-treat and drug-resistant fungal infections.
Ibrexafungerp is the first representative of this novel class of antifungals and was approved by the U.S.
REMOVED
Excludes 382,783 shares of the registrant's Common Stock held by executive officers and directors outstanding at June 28, 2024.
As of March 1, 2025, there were 38,981,064 shares of the registrant s Common Stock outstanding .
The following is a summary of the principal risk factors: We may not be able to realize the benefits we expect under our license agreement with GlaxoSmithKline Intellectual Property (No.
3) Limited (GSK) if we are not able to develop ibrexafungerp.
We have a limited history of profitability, we have only one product approved for commercial sale that is licensed to GSK and is subject to a product recall, and to date we have generated limited revenue from product sales.
Although both the oral and IV formulations of ibrexafungerp have been granted Qualified Infectious Disease Product status and Fast Track designation, this does not guarantee that the length of the FDA review process will be significantly shorter than otherwise, or that ibrexafungerp will ultimately be approved by the FDA.
We expect that BREXAFEMME, ibrexafungerp for the treatment of other indications and any future product candidates we may seek to develop will face competition, and most of our competitors have significantly greater resources than we do.
BREXAFEMME, ibrexafungerp, or any other future product candidates we may seek to develop, may still face future development and regulatory difficulties.
If we experience problems with any of these third parties, the commercial manufacturing of ibrexafungerp could be delayed.
is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →